REFERENCES
16. Laube B, Georgopoulos A, Adams G. Preliminary study of the efficacy of insulin aero-


44. De Meer G, Heederik D, Postma DS. Bronchial Responsiveness to Adenosine 5’-Monophosphate (AMP) and Methacholine Differ in Their Relationship with Airway Allergy and Baseline FEV1. Am J Respir Crit Care Med 2002;165:327–331.


formoterol compared with formoterol, salbutamol and placebo on repeated provocations with inhaled AMP in patients with asthma: A randomised, double-blind, crossover study. Respir Res 2010;11:66.


75. Wong-Chew RM, Islas-Romero R, García-Garcia MDL, Beeler JA, Audet S, Santos-Preciado JJ, et al. Induction of cellular and humoral immunity after aerosol or subc-
90. Rave K, Bott S, Heinemann L, Sha S, Becker RHA, Willavize SA, et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and
References


105. European Medicines Agency, Committee for Medicinal Products for Human use (CHMP). Reflection paper: Formulations of choice for the paediatric population. Lon-
don, 2006.


156. Lavorini F. The Challenge of Delivering Therapeutic Aerosols to Asthma Patients. ISRN Allergy 2013;102418.


178. Price R, Young PM, Edge S, Staniforth JN. The influence of relative humidity on par-


References

222. Polosa R, Holgate ST, Church MK. Adenosine as a pro-inflammatory mediator in asth-
References


321. Personal communication Dr. RE Sievers.


References


